Glipizide – 5 g

Brand:
Cayman
CAS:
29094-61-9
Storage:
-20
UN-No:
Non-Hazardous - /

Glipizide is a hypoglycemic agent.{46791} It inhibits ATP-sensitive potassium (KATP) channels in primary mouse pancreatic β cells (IC50 = 6.4 nM). Glipizide induces insulin release from isolated rat pancreatic tissue with an EC50 value of 40 nM.{46792} Dietary administration of glipizide (5 mg/kg per day for 10 days) increases the number of insulin receptors on isolated and purified mouse liver plasma membranes.{46793} It reduces plasma glucose and triglyceride, but not total cholesterol, levels and increases plasma insulin levels in a rat model of diabetes induced by a high-fat diet and streptozotocin (STZ; Item No. 13104) when administered orally at a dose of 5 mg/kg.{46794} Formulations containing glipizide have been used in the treatment of type 2 diabetes.  

 

Available on backorder

SKU: 11579 - 5 g Category:

Description

A hypoglycemic agent; inhibits KATP channels in primary mouse pancreatic β cells (IC50 = 6.4 nM); induces insulin release from isolated rat pancreatic tissue (EC50 = 40 nM); increases the number of insulin receptors on isolated and purified mouse liver plasma membranes at 5 mg/kg per day for 10 days in the diet; reduces plasma glucose and triglyceride, but not total cholesterol, levels and increases plasma insulin levels in a rat model of diabetes induced by a high-fat diet and STZ at 5 mg/kg, p.o.


Formal name: N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-2-pyrazinecarboxamide

Synonyms:  CP 28720|K 4024|TK 1320

Molecular weight: 445.5

CAS: 29094-61-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Ion Channel Modulation|Blockers||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias